Reply and the University of Milan Launch Experimental Research on Biological Computing Based on Cortical Labs’ CL1 Platform
28.1.2026 15:10:00 CET | Business Wire | Press Release
Reply [EXM, STAR: REY] today announced the start of a collaboration with the Department of Pathophysiology and Transplantation of the University of Milan, together with the “Centro Dino Ferrari” of the University of Milan - Ospedale Policlinico, for a new research and experimental initiative in the field of biological computing. The project aims to explore innovative approaches to learning and information processing through the integration of biological systems and digital technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128715625/en/
This initiative represents the starting point of an advanced research programme aimed at exploring new computational paradigms.
At the core of the initiative is the CL1 biological computer developed by Cortical Labs, an Australian biotechnology company. Unlike conventional silicon-based computing architectures, this technology leverages the processing capabilities of living human neurons integrated with software systems. The CL1 platform incorporates approximately 800,000 neurons, which receive inputs, process information, and generate outputs in the form of electrical activity, enabling direct interaction between the software and biological intelligence.
Building on previous studies conducted by Cortical Labs, which demonstrated that neuronal cultures can learn the game Pong in just a few minutes using significantly fewer training examples than conventional artificial intelligence systems, the Reply–University of Milan research project will focus on analyzing the learning dynamics of biological neurons, comparing their energy efficiency with traditional computing architectures, and assessing the robustness, reproducibility, and long-term stability of neuron-based computing systems.
“This initiative represents the starting point of an advanced research programme aimed at exploring new computational paradigms. The goal is to assess their potential practical impact and to understand their possible implications in terms of solutions and benefits for organisations,” said Filippo Rizzante, CTO of Reply.
“This collaboration opens a new frontier in the study of biological computation,” stated Prof. Stefania Corti, Full Professor of Neurology at the University of Milan and Director of Neuromuscular and Rare Diseases at the Milan Policlinico. “The integration of active neurons with digital systems offers unprecedented opportunities to investigate learning mechanisms and neural plasticity, with potential implications for both neuroscience research and computational innovation.”
“Working with biological neurons in a computational context allows us to explore fundamental questions about how neural networks process and adapt to information,” added Prof. Linda Ottoboni, Researcher at the Department of Medical-Surgical Pathophysiology and Transplantation of the University of Milan. “This interdisciplinary project combines neuroscientific expertise with cutting-edge technologies to advance our understanding of biological intelligence.”
“The CL1 platform offers a unique opportunity to study the physiological dynamics of neuronal networks in a controlled computational environment,” said Prof. Carlo Capelli, Full Professor of Physiology at the Department of Medical-Surgical Pathophysiology and Transplantation of the University of Milan. “Understanding how biological systems process information at the cellular level could open new perspectives in integrative physiology research.”
“From a biomechanical and physiological standpoint, this project allows us to investigate the energy efficiency of biological computation compared to artificial systems,” added Prof. Alberto Minetti, Full Professor of Physiology and Biomechanics at the University of Milan. “The potential for studying adaptive mechanisms in living neural networks is remarkable. The results of simple dynamic balance experiments, for example, could be achieved using a significantly smaller number of ‘biological’ neurons.”
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
University of Milan – Department of Pathophysiology and Transplantation
The Department of Pathophysiology and Transplantation of the University of Milan is a center of excellence in biomedical research focused on translational medicine. Its activities range from cellular physiology to neuroscience and the development of advanced therapeutic strategies, with the aim of translating scientific discoveries into clinical and technological innovation. Researchers involved: Prof. Stefania Corti and Prof. Linda Ottoboni, Dino Ferrari Center, University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Italy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128715625/en/
Contacts
Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 0117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
University of Milan
Press Office, University of Milan
ufficiostampa@unimi.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo ® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press Release
Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other European countries and plans to complete the rollout across Europe by the end of the year. Celltrion is offering Omlyclo® 300 mg in both pre-filled syringe (PFS) and autoinjector (AI) presentations, allowing patients and healthcare professionals a choice of device depending on the treatment setting and individual patient needs. This comprehensive port
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press Release
Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity verification, we're able to offer unprecedented security, performance, and innovation. Organisations can now accelerate their digital transformation
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press Release
SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press Release
Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press Release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom